BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 18374301)

  • 1. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB; Heller W; Shapiro AM; Si E; Hsu P; Bowman LM;
    Am J Ophthalmol; 2008 Jun; 145(6):959-65. PubMed ID: 18374301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
    Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
    Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
    Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
    Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
    Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
    Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
    J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
    Protzko E; Bowman L; Abelson M; Shapiro A;
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
    Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
    Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
    Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
    Comstock TL; Paterno MR; Usner DW; Pichichero ME
    Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
    Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
    Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis].
    Ambroziak AM; Szaflik JP; Hapunik A
    Klin Oczna; 2009; 111(1-3):46-9. PubMed ID: 19517846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of symptom resolution in adults with acute bacterial rhinosinusitis treated with a single dose of azithromycin extended release compared with 10 days of levofloxacin: a retrospective analysis of a randomized, double-blind, double-dummy trial.
    Marple BF; Roberts CS; de Caprariis PJ; Reisman A
    Clin Ther; 2007 Dec; 29(12):2690-8. PubMed ID: 18201585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis.
    Luchs J
    Adv Ther; 2008 Sep; 25(9):858-70. PubMed ID: 18781287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis.
    Haque RM; Torkildsen GL; Brubaker K; Zink RC; Kowalski RP; Mah FS; Pflugfelder SC
    Cornea; 2010 Aug; 29(8):871-7. PubMed ID: 20508503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study.
    Block SL; Cifaldi M; Gu Y; Paris MM
    Clin Ther; 2005 Jun; 27(6):786-94. PubMed ID: 16117986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.